文献速递肝病消化道肿瘤与早癌

2002-2033年MAFLD相关肝细胞癌的流行病学趋势与轨迹:ITA.LI.CA数据库

Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.
PubMed 文献 · Gut · 2021-12-21

研究分析意大利23个肝癌中心2002-2019年连续纳入的6882例HCC患者,比较单纯MAFLD、混合病因MAFLD与非MAFLD三组的流行病学及未来趋势。结果显示MAFLD HCC占68.4%且比例随时间显著上升,单纯MAFLD HCC预计约6年内超过混合病因MAFLD HCC;单纯MAFLD HCC诊断时肿瘤分期较不利,但HCC相关死亡风险显著更低。

要点

  • MAFLD HCC占HCC患者的68.4%,单纯MAFLD HCC比例从2002-2003年3.6%升至2018-2019年28.9%。
  • 单纯MAFLD HCC患者更老、更多男性、更少肝硬化及临床相关门脉高压,更多大肿瘤和肝外转移。
  • 加权后单纯MAFLD和混合病因MAFLD的HCC相关死亡风险均显著低于非MAFLD。

核心结论

  • 意大利MAFLD HCC患病率快速上升,将覆盖大多数HCC患者;尽管诊断时肿瘤分期较不利,MAFLD HCC患者HCC相关死亡风险更低,提示肿瘤侵袭性较低。

研究设计与样本

  • 研究分析了2002年至2019年由23个意大利肝癌中心连续纳入的6882例HCC患者,比较单纯MAFLD、混合病因MAFLD和非MAFLD HCC三个亚组的流行病学与未来趋势。

主要发现

  • MAFLD HCC占多数患者(68.4%);总MAFLD和单纯MAFLD HCC比例随时间显著增加(分别从2002-2003年50.4%和3.6%升至2018-2019年77.3%和28.9%,p<0.001)。
  • 在意大利,单纯MAFLD HCC预计约6年内超过混合病因MAFLD HCC。
  • 单纯MAFLD HCC患者年龄更大、更多男性、更少肝硬化及临床相关门脉高压、更少监测相关诊断,更多大肿瘤和肝外转移。
  • 加权后,与非MAFLD相比,单纯MAFLD和混合病因MAFLD HCC的总死亡风险显著更低(p=0.026,p=0.004),HCC相关死亡风险也显著更低(两者p<0.001)。
  • 单纯MAFLD HCC患者非HCC相关死亡风险显著更高(p=0.006)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metabolic dysfunction-associated fatty liver disease (MAFLD) represents a new inclusive definition of the whole spectrum of liver diseases associated to metabolic disorders. The main objective of this study was to compare patients with MAFLD and non-MAFLD with hepatocellular carcinoma (HCC) included in a nationally representative cohort. METHODS: We analysed 6882 consecutive patients with HCC enrolled from 2002 to 2019 by 23 Italian Liver Cancer centres to compare epidemiological and future trends in three subgroups: pure, single aetiology MAFLD (S-MAFLD); mixed aetiology MAFLD (metabolic and others, M-MAFLD); and non-MAFLD HCC. RESULTS: MAFLD was diagnosed in the majority of patients with HCC (68.4%). The proportion of both total MAFLD and S-MAFLD HCC significantly increased over time (from 50.4% and 3.6% in 2002-2003, to 77.3% and 28.9% in 2018-2019, respectively, p<0.001). In Italy S-MAFLD HCC is expected to overcome M-MAFLD HCC in about 6 years. Patients with S-MAFLD HCC were older, more frequently men and less frequently cirrhotic with clinically relevant portal hypertension and a surveillance-related diagnosis. They had more frequently large tumours and extrahepatic metastases. After weighting, and compared with patients with non-MAFLD, S-MAFLD and M-MAFLD HCC showed a significantly lower overall (p=0.026, p=0.004) and HCC-related (p<0.001, for both) risk of death. Patients with S-MAFLD HCC showed a significantly higher risk of non-HCC-related death (p=0.006). CONCLUSIONS: The prevalence of MAFLD HCC in Italy is rapidly increasing to cover the majority of patients with HCC. Despite a less favourable cancer stage at diagnosis, patients with MAFLD HCC have a lower risk of HCC-related death, suggesting reduced cancer aggressiveness.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Vitale A, Svegliati-Baroni G, Ortolani A, et al. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. Gut. 2021. PMID: 34933916. doi:10.1136/gutjnl-2021-324915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。